Research programme: immunomodulatory therapeutics - AlphaRx/PharmaSeed

Drug Profile

Research programme: immunomodulatory therapeutics - AlphaRx/PharmaSeed

Latest Information Update: 23 Sep 2011

Price : $50

At a glance

  • Originator AlphaRx; PharmaSeed
  • Developer AlphaRx
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Immunological disorders

Most Recent Events

  • 05 Jul 2011 Discontinued - Preclinical for Immunological disorders in Israel (unspecified route)
  • 05 Jul 2011 Discontinued - Preclinical for Immunological disorders in Canada (unspecified route)
  • 11 May 2006 Preclinical trials in Immunological disorders in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top